Published in
Springer, Investigational New Drugs, 2(33), p. 397-408, 2015
DOI: 10.1007/s10637-014-0199-x
Links
Tools
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer
Journal article published in 2015 by
Daniel P. Petrylak,
Jitendra G. Gandhi,
William R. Clark,
Elisabeth Heath,
Jianqing Lin,
William K. Oh,
David B. Agus,
Bradley Carthon,
Susan Moran 
,
Ning Kong,
Ajit Suri,
Michael Bargfrede,
Glenn Liu
,
Ning Kong,
Ajit Suri,
Michael Bargfrede,
Glenn Liu
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 